Details for New Drug Application (NDA): 206551
✉ Email this page to a colleague
NDA 206551 describes BIVALIRUDIN, which is a drug marketed by Accord Hlthcare, Apotex, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hospira, Meitheal, Mylan Institutional, Shuangcheng, Slate Run Pharma, and Baxter Hlthcare Corp, and is included in twelve NDAs. It is available from ten suppliers. Additional details are available on the BIVALIRUDIN profile page.
The generic ingredient in BIVALIRUDIN is bivalirudin. There are fourteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
The generic ingredient in BIVALIRUDIN is bivalirudin. There are fourteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for 206551
| Tradename: | BIVALIRUDIN |
| Applicant: | Accord Hlthcare |
| Ingredient: | bivalirudin |
| Patents: | 0 |
Pharmacology for NDA: 206551
| Mechanism of Action | Thrombin Inhibitors |
Suppliers and Packaging for NDA: 206551
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 206551 | ANDA | Accord Healthcare, Inc. | 16729-275 | 16729-275-67 | 10 VIAL, SINGLE-USE in 1 CARTON (16729-275-67) / 5 mL in 1 VIAL, SINGLE-USE (16729-275-03) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 250MG/VIAL | ||||
| Approval Date: | Nov 22, 2017 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
